Romero CA, Mathew S, Wasinski B, et al. - Among African American patients with hypertension and left ventricular hypertrophy (LVH), how anti‐fibrotic biomarkers could be impacted by treatment with angiotensin‐converting enzyme inhibitors (ACEi) was assessed in this post hoc analysis of a randomized controlled trial (wherein hypertensive African American patients with LVH and vitamin D deficiency were randomly assigned to intensive antihypertensive therapy plus vitamin D supplementation or placebo). Patients who had detectable lisinopril (lisinopril group) in plasma were selected and were compared with individuals who did not (comparison group) at the one‐year follow‐up. Lower blood pressure was detected in patients with detectable lisinopril vs those in the comparison group. Patients with detectable ACEi were found to have higher anti‐fibrotic markers Ac‐SDKP (N‐acetyl‐seryl‐aspartyl‐lysyl‐proline), MMP‐1 (matrix metalloproteinase‐1), and MMP‐1/TIMP‐1 (tissue inhibitor of metalloproteinases 1) ratio. Based on findings, it was inferred that an increase in anti‐fibrotic biomarkers, in African American patients with hypertension and LVH, is brought about by treatment with ACEi, this indicates that ACEi may confer added benefit over other agents in such patients.